Table 3.

Overall response rate, overall survival, and progression-free survival in all patients and TMB/PD-L1 subgroups

Population	ORR, %	Median PFS (95% CI), months	Median OS (95% CI), months	Tumor PD-L1 expression	ORR, %	Median PFS (95% CI), months	Median OS (95% CI), months
All treated patients N = 270	20.7	1.9 (1.9–2.3)	8.6 (6.1–11.3)	<1% n = 146	16.4	1.9 (1.7–2.0)	6.0 (4.4–8.1)
				≥1% n = 124	25.8	3.5 (1.9–3.7)	11.9 (9.1–19.1)
TMB-evaluable patients n = 139	21.6	1.9 (1.8–2.8)	7.2 (5.5–11.4)	<1% n = 69	18.8	1.8 (1.7–2.2)	5.7 (4.2–11.3)
				≥1% n = 70	24.3	2.3 (1.9–3.7)	10.3 (5.8–17.1)
TMB low n = 46	13.0	1.9 (1.8–3.1)	5.7 (3.6–10.9)	<1% n = 25	4.0	1.8 (1.6–2.0)	5.0 (2.8–10.4)
				≥1% n = 21	23.8	3.1 (1.9–5.7)	8.6 (3.6–17.1)
TMB medium n = 46	19.6	1.8 (1.7–2.3)	9.7 (4.5–16.4)	<1% n = 21	23.8	1.8 (1.4–3.7)	4.5 (2.2–16.4)
				≥1% n = 25	16.0	1.9 (1.6–3.4)	11.3 (5.5–19.1)
TMB high n = 47	31.9	3.5 (1.8–14.0)	11.6 (5.7–33.5)	<1% n = 23	30.4	2.5 (1.7–19.5)	20.9 (4.2–33.5)
				≥1% n = 24	33.3	3.5 (1.7–22.3)	10.6 (4.6–NE)

NE, not estimable.